Privo Technologies expands to a new 3000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place, Suite 6B in Peabody, Massachusetts, the new facility consists of two seperate research labs that will be used in...
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral cancer treatments to additional patent protection, 7 years of drug exclusivity, and tax credits equal to 50% of research...
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Buccal Delivery of Chemotherapy to treat.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the company’s drug development activities. We are proud to receive these very competitive awards and honored to be amongst some...
- © Web Design & Development
- © UX Strategy & Digital Branding